Treatment for viral respiratory infections: Principles of action, strategies, and future prospects;Therapie viraler atemwegsinfekte: Wirkprinzipien, strategien und ausblicke

Internist

Volumn 45, Issue 4, 2004, Pages 468-475

  Rohde, G ^a   Schultze Werninghaus, G ^a   Bauer, T T ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Antiviral treatment; Influenza; Neuraminidase inhibitors; Pulmonary infection; Viral infection

Indexed keywords

ALPHA INTERFERON; AMANTADINE; CIDOFOVIR; OSELTAMIVIR; PALIVIZUMAB; PLECONARIL; RIBAVIRIN; SIALIDASE INHIBITOR; ZANAMIVIR;

ADENOVIRUS; ANEMIA; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; BRONCHOSPASM; CLINICAL TRIAL; CONFERENCE PAPER; CORONAVIRUS; DEPRESSION; DIARRHEA; DRUG EFFICACY; EMBRYOTOXICITY; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INSOMNIA; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PARAINFLUENZA VIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RHINOVIRUS; SIDE EFFECT; SOCIOECONOMICS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; VIRUS CELL INTERACTION; VIRUS INFECTION;

ANTIVIRAL AGENTS; GUANIDINES; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; PHYSICIAN'S PRACTICE PATTERNS; PYRANS; RESPIRATORY TRACT INFECTIONS; SIALIC ACIDS; TREATMENT OUTCOME; VIRUS DISEASES; ZANAMIVIR;

EID: 2942517917     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1111-5     Document Type: Conference Paper

References (65)

1. Denny FW (1995) The clinical impact of human respiratory virus infections. Am J Respir Crit Care Med 152: S4-12
2. Adams PF, Herdershot GE, Marano MA (1999) Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat 10
3. Fendrick AM, Monto AS, Nightengale B, Sarnes M (2003) The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med 163: 487-494
4. Johnston SL (1995) Natural and experimental rhinovirus infections of the lower respiratory tract. Am J Respir Crit Care Med 152: S46-S52
5. Rohde G, Wiethege A, Borg I et al. (2003) Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization - a case-control study. Thorax 58: 37-42
6. Seemungal T, Harper-Owen R, Bhowmik A et al. (2001) Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: 1618-1623
7. Seemungal TAR, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA (2000) Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. Eur Respir J 16: 677-683
8. Jefferson TO, Tyrrell D (2003) Antivirals for the common cold. Cochrane Rev 3rd edn.
9. Higgins PG, Barrow GI, Galbraith AW, Frost H, Tyrrell DA (1989) A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2 infection in human volunteers. Antiviral Res 12: 49-52
10. Gwaltney JM (1992) Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 166: 776-782
11. Kuzmov K, Galabov AS, Radeva K, Kozhukharova M, Milanov K (1985) Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases. Z Mikrobiol Epidemiol Immunobiol 26-30
12. Kahlich R, Klima J, Cihla F et al. (1979) Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J Hyg Epidemiol Microbiol Immunol 23: 11-24
13. Rotbart HA (2000) Pleconaril treatment of enterovirus and rhinovirus infections. Infect Med 17: 488-494
14. Kearns GL, Abdel-Rahman SM, James LP et al. and the Pediatric Pharmacology Research Unit Network (1999) Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Antimicrob Agents Chemother 43: 634-638
15. Schiff GM, Sherwood JR (2000) Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection. J Infect Dis 181: 20-26
16. Rogers JM, Diana GD, McKinlay MA (1999) Pleconaril. A broad spectrum antipicornaviral agent. Adv Exp Med Biol 458: 69-76
17. Pevear DC, Tull TM, Seipel ME, Groarke JM (1999) Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43: 2109-2115
18. Hayden FG, Herrington DT, Coats TL et al. (2003) Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 36: 1523-1532
19. McKinlay MA (2001) Recent advances in the treatment of rhinovirus infections. Curr Opin Pharmacol 1: 477-481
20. Turner RB, Wecker MT, Pohl G et al.(1999) Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 281: 1797-1804
21. Anzueto A, Niederman MS (2003) Diagnosis and treatment of rhinovirus respiratory infections. Chest 123: 1664
22. Togo Y, Hornick RB, Felitti VJ et al. (1970) Evaluation of therapeutic efficacy of amantadine in patients with naturally occurring A2 influenza. JAMA 211: 1149-1156
23. Wingfield WL, Pollack D, Grunert RR (1969) Therapeutic efficacy of amantadine HCI and rimantadine HCI in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 281: 579-584
24. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S (1991) Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 35: 1741-1747
25. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J, Reilly L, Keene O (2000) Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 19: 410-417
26. Lalezari J, Campion K, Keene O, Silagy C (2001) Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med 161: 212-217
27. Makela MJ, Pauksens K, Rostila T et al. (2000) Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 40: 42-48
28. The MIST (Management of influenza in the Southern Hemisphere Trialists) Study Group (1998) Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352: 1877-1881
29. Griffin AD, Perry AS, Fleming DM (2001) Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients. Pharmacoeconomics 19: 293-301
30. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A (1999) Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 282: 31-35
31. Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M (2001) Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 322: 577-579
32. Hayden FG, Atmar RL, Schilling M et al. (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341: 1336-1343
33. Nicholson KG, Aoki FY, Osterhaus AD et al. (2000) Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355: 1845-1850
34. Whitley RJ, Hayden FG, Reisinger KS et al. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127-133
35. Hayden FG, Treanor JJ, Fritz RS et al. (1999) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282: 1240-1246
36. Peters PH, Gravenstein S, Norwood P et al. (2001) Long-term use of oseltamivir for the prophylaxis of infiuenza influenza in a vaccinated frail older population. J Am Geriatr Soc 49: 1025-1031
37. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG (2003) Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 326: 1235
38. Stiver G (2003) The treatment of influenza with antiviral drugs. Can Med Assoc J 168: 49-56
39. Edwards KM, Thompson J, Paolini J, Wright PF (1985) Adenovirus infections in young children, Pediatrics 76: 420-424
40. Fox JP, Hall Ce, Cooney MK (1977) The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 105: 362-386
41. Hierholzer JC (1992) Adenoviruses in the immunocompromised host. Clin Microbiol Rev 5: 262-274
42. Gavin PJ, Katz BZ (2002) Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 110: e9
43. Ribaud P, Scieux D, Freymuth F, Morinet F, Gluckman E (1999) Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis 28: 690-691
44. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (1972) Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177: 705-706
45. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A (2001) Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 32: 1290-1297
46. Sherman DS, Fish DN (1999) Cidofovir. AIDS Read 9: 215-220
47. Simoes EAF (1999) Respiratory syncytial virus infection. Lancet 354: 847-852
48. Black CP (2003) Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 48: 209-231
49. Taber LH, Knight V, Gilbert BE et al. (1983) Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72: 613-618
50. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC (1985) Ribavirin treatment of respiratory syncytial viral infection in infants with undedying cardiopulmonary disease. JAMA 254: 3047-3051
51. Smith DW, Frankel LR, Mathers LH et al. (1991) A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 325: 24-29
52. Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW (1994) Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 22: 566-572
53. Law BJ, Wang EE, MacDonald N et al. (1997) Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics 99: E7
54. Johnson S, Oliver C, Prince GA et al. (1997) Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215-1224
55. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537
56. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA (1999) Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 104: 419-427
57. Rotbart HA, Hayden FG (2000) Picornavirus infections: a primer for the practitioner. Arch Fam Med 9: 913-920
58. Castellano F, Mautone G (2002) Decongestant activity of a new formulation of xylometazoline nasal spray: a double-blind, randomized versus placebo and reference drugs controlled, dose-effect study. Drugs Exp Clin Res 28: 27-35
59. Stanley ED, Jackson GG, Panusarn C, Rubenis M, Dirda V (1975) Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA 231: 1248-1251
60. Koytchev R, Vlahov V, Bacratcheva N et al. (2003) Evaluation of the efficacy of a combined formulation (Grippostad-C) in the therapy of symptoms of common cold: a randomized, double-blind, multicenter trial. Int J Clin Pharmacol Ther 41: 114-125
61. McElroy BH, Miller SP (2002) Effectiveness of zinc gluconate glycine lozenges (Cold-Eeze) against the common cold in school-aged subjects: a retrospective chart review. Am J Ther 9: 472-475
62. Van Straten M, Josling P (2002) Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey. Adv Ther 19: 151-159
63. Pitkäranta A, Hayden FG (1998) What's new with common colds? Complications and management. Infect Med 15: 117-128
64. Gadomski AM (1993) Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections. Pediatr Infect Dis J 12: 115-120
65. Zetkin M, Schaldach H (1999) Lexikon der Medizin, 16. Aufl. Ullstein Medical, München